Rituximab in Severe Pemphigus

被引：89
作者：
Schmidt, Enno [1 ]
Goebeler, Matthias [2 ]
Zillikens, Detlef [1 ]
机构：
[1] Med Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany
[2] Univ Heidelberg, Univ Hosp Mannheim, Dept Dermatol, D-6800 Mannheim, Germany
来源：
CONTEMPORARY CHALLENGES IN AUTOIMMUNITY | 2009年 / 1173卷
关键词：
autoantibody; desmoglein pemphigus; foliaceus; MabThera (TM); pemphigus vulgaris; Rituxan (TM); therapy; treatment; B-CELL DEPLETION; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CHRONIC LYMPHOCYTIC-LEUKEMIA; AUTOIMMUNE BULLOUS DISEASES; PROTEIN-A IMMUNOADSORPTION; PARANEOPLASTIC PEMPHIGUS; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; ANTI-CD20; ANTIBODY; ADJUVANT TREATMENT;
D O I：
10.1111/j.1749-6632.2009.04744.x
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Pemphigus is a life-threatening autoimmune bullous disorder that requires long-term treatment with systemic corticosteroids mostly in conjunction with further immunosuppressants. Rituximab has opened a new avenue for severe and refractory pemphigus patients. In 95% of the 136 pemphigus patients reported to date in the English, French, and German literature, at least a partial remission has been achieved. In about two-thirds of communicated cases, application of rituximab resulted in the healing of an lesions. A controlled prospective study, however, has only recently being initiated. In pemphigus, rituximab is aimed at resetting the immune system to a condition in which autoreactive B lymphocytes are eliminated or sufficiently controlled. Here, we review mechanisms of action, different treatment protocols, clinical responses, and the safety profile of rituximab.
引用
收藏
页码：683 / 691
页数：9
相关论文
共 53 条
[1]   Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin [J].
Ahmed, A. Razzaque ;
Spigelman, Zachary ;
Cavacini, Lisa A. ;
Posner, Marshall R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (17) :1772-1779
[2]   Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment [J].
Ahmed, AR .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 45 (05) :679-690
[3]   Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus [J].
Albert, D. ;
Dunham, J. ;
Khan, S. ;
Stansberry, J. ;
Kolasinski, S. ;
Tsai, D. ;
Pullman-Mooar, S. ;
Barnack, F. ;
Striebich, C. ;
Looney, R. J. ;
Prak, E. T. Luning ;
Kimberly, R. ;
Zhang, Y. ;
Eisenberg, R. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (12) :1724-1731
[4]   Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus [J].
Anolik, JH ;
Barnard, J ;
Cappione, A ;
Pugh-Bernard, AE ;
Felgar, RE ;
Looney, RJ ;
Sanz, I .
ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3580-3590
[5]   The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus [J].
Anolik, JH ;
Campbell, D ;
Felgar, RE ;
Young, F ;
Sanz, I ;
Rosenblatt, J ;
Looney, RJ .
ARTHRITIS AND RHEUMATISM, 2003, 48 (02) :455-459
[6]   The potential utility of B cell-directed biologic therapy in autoimmune diseases [J].
Arkfeld, D. G. .
RHEUMATOLOGY INTERNATIONAL, 2008, 28 (03) :205-215
[7]   The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases [J].
Boren, Eric J. ;
Cheema, Gurtej S. ;
Naguwa, Stanley M. ;
Ansari, Aftab A. ;
Gershwin, M. Eric .
JOURNAL OF AUTOIMMUNITY, 2008, 30 (1-2) :90-98
[8]   B cells move to centre stage: novel opportunities for autoimmune disease treatment [J].
Browning, Jeffrey L. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (07) :564-576
[9]   The adjuvant therapy of pemphigus - An update [J].
Bystryn, JC ;
Steinman, NM .
ARCHIVES OF DERMATOLOGY, 1996, 132 (02) :203-212
[10]   Treatment of severe pemphigus with rituximab - Report of 12 cases and a review of the literature [J].
Cianchini, Giuseppe ;
Corona, Rosamaria ;
Frezzolini, Alessandra ;
Ruffelli, Marina ;
Didona, Biagio ;
Puddu, Pietro .
ARCHIVES OF DERMATOLOGY, 2007, 143 (08) :1033-1038
123456